Bryan Tordon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Bryan Tordon has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Akash Gupta
National Platelet Immunology Reference Laboratory Canadian Blood Services Brampton Ontario Canada
1 shared publication Amie Malkin
Precision Diagnostics and Therapeutics Program Sunnybrook Health Sciences Centre Toronto Ontario Canada
1 shared publicationAmy Moorehead
Hematology Oncology Clinical Research Group, St. Michael's Hospital Toronto Ontario Canada
1 shared publicationAnn Peregrin
National Platelet Immunology Reference Laboratory Canadian Blood Services Brampton Ontario Canada
1 shared publicationCelina Montemayor
Canadian Blood Services, Medical Affairs and Innovation Toronto Ontario Canada
1 shared publication- Christine Cserti‐Gazdewich
Department of Laboratory Medicine and Pathobiology University of Toronto Toronto Ontario Canada
1 shared publication
Latest Publications
- Open Access
- 11 February 2026
- Published by Wiley in Vox Sanguinis
- Vol. 121 (5) , 643-648
Investigating human platelet antigens and antibodies in pregnancy: An 11‐year experience from a Canadian reference laboratory
Background and Objectives: Foetal and neonatal alloimmune thrombocytopaenia (FNAIT) is a potentially severe immune‐mediated condition that is believed to be under‐identified in the Canadian population. The Canadian Blood Services National Platelet Immunology Reference Laboratory (NPIRL) serves as a centralized referral laboratory for FNAIT investigations across Canada. Diagnostic evaluation includes human platelet antigen (HPA) genotyping and maternal anti‐HPA antibody testing. This study is a review of all FNAIT investigations referred to NPIRL to assess testing patterns, antibody detection rates and evidence of under identification at a national level. Materials and Methods: All maternal, paternal and neonatal samples related to FNAIT investigations between 20 January 2014 and 31 December 2024 were extracted from the NPIRL database. The geographic origin of samples, HPA genotyping and antibody specificity, if present, were documented. Results: A total of 1986 samples (1076 maternal, 620 paternal and 290 neonatal) were received for FNAIT investigation over the 11‐year study period. One‐hundred and thirty‐five HPA antibodies were identified in 130 of the maternal samples tested, with anti‐HPA‐1a and HPA‐5b being the most frequently detected specificities. Despite a modest increase in annual referrals, the total number of investigations and antibody‐positive cases was substantially lower than expected based on Canadian birth rates and published FNAIT incidence estimates. Conclusion: Referral patterns and laboratory findings from NPIRL demonstrate a marked discrepancy between expected FNAIT incidence and observed diagnostic activity in Canada, indicating that FNAIT is substantially under‐identified. These findings highlight the need for improved recognition, standardized investigation pathways and enhanced diagnostic strategies to reduce missed cases and improve neonatal outcomes.
- 11 February 2026
- Published by Wiley in Vox Sanguinis
- Vol. 121 (5) , 643-648
Open AccessInvestigating human platelet antigens and antibodies in pregnancy: An 11‐year experience from a Canadian reference laboratory
Background and Objectives: Foetal and neonatal alloimmune thrombocytopaenia (FNAIT) is a potentially severe immune‐mediated condition that is believed to be under‐identified in the Canadian population. The Canadian Blood Services National Platelet Immunology Reference Laboratory (NPIRL) serves as a centralized referral laboratory for FNAIT investigations across Canada. Diagnostic evaluation includes human platelet antigen (HPA) genotyping and maternal anti‐HPA antibody testing. This study is a review of all FNAIT investigations referred to NPIRL to assess testing patterns, antibody detection rates and evidence of under identification at a national level. Materials and Methods: All maternal, paternal and neonatal samples related to FNAIT investigations between 20 January 2014 and 31 December 2024 were extracted from the NPIRL database. The geographic origin of samples, HPA genotyping and antibody specificity, if present, were documented. Results: A total of 1986 samples (1076 maternal, 620 paternal and 290 neonatal) were received for FNAIT investigation over the 11‐year study period. One‐hundred and thirty‐five HPA antibodies were identified in 130 of the maternal samples tested, with anti‐HPA‐1a and HPA‐5b being the most frequently detected specificities. Despite a modest increase in annual referrals, the total number of investigations and antibody‐positive cases was substantially lower than expected based on Canadian birth rates and published FNAIT incidence estimates. Conclusion: Referral patterns and laboratory findings from NPIRL demonstrate a marked discrepancy between expected FNAIT incidence and observed diagnostic activity in Canada, indicating that FNAIT is substantially under‐identified. These findings highlight the need for improved recognition, standardized investigation pathways and enhanced diagnostic strategies to reduce missed cases and improve neonatal outcomes.
- Open Access
- 1 October 2024
- Published by Wiley in Transfusion
- Vol. 64 (12) , 2371-2379
Correlation of the Transfusion Camp knowledge assessment test with clinical transfusion practice
Background: It is uncertain how transfusion knowledge translates to practice. The purpose of the study was to determine if higher scores on a validated Transfusion Camp knowledge assessment test were associated with transfusion order appropriateness.Study Design and Methods: Eligible participants included postgraduate trainees and faculty physicians who had prescribed at least four transfusion orders in the preceding 6 months at two hospitals. Participant data and knowledge were collected using a web‐based questionnaire with a validated Transfusion Camp knowledge assessment tool. The most recent 4–10 consecutive transfusion orders per prescriber were independently dually adjudicated for appropriateness based on published criteria. The primary outcome was the correlation between the score on six questions on red blood cells (RBCs), platelets (PLTs), and plasma from the validated test and the percentage order appropriateness. Generalized linear regression was conducted to determine if factors (sex, specialty, participation in Transfusion Camp, previous transfusion education, self‐rated knowledge) were associated with appropriate orders.Results: Seventy‐four participants (45 trainees, 29 faculty; 31 females, 43 males) completed the test. Median score was 66.7% (interquartile range [IQR]: 50.0, 83.3) for six questions on RBCs, PLTs, and plasma transfusions. Of 546 transfusion orders adjudicated, appropriateness was 90.7% (95% confidence interval [CI]: 87.9%–93.0%). The correlation between prescriber test scores and order appropriateness was very weak (r = −.08). In multivariable analysis, female prescribers (p = .02) and beginner (vs. intermediate) self‐rated knowledge (p = .01) were associated with higher transfusion appropriateness.Conclusion: Transfusion knowledge test scores did not correlate with order appropriateness. Factors other than knowledge are key to understanding how to improve appropriate blood use.
- 1 October 2024
- Published by Wiley in Transfusion
- Vol. 64 (12) , 2371-2379
Open AccessCorrelation of the Transfusion Camp knowledge assessment test with clinical transfusion practice
Background: It is uncertain how transfusion knowledge translates to practice. The purpose of the study was to determine if higher scores on a validated Transfusion Camp knowledge assessment test were associated with transfusion order appropriateness.Study Design and Methods: Eligible participants included postgraduate trainees and faculty physicians who had prescribed at least four transfusion orders in the preceding 6 months at two hospitals. Participant data and knowledge were collected using a web‐based questionnaire with a validated Transfusion Camp knowledge assessment tool. The most recent 4–10 consecutive transfusion orders per prescriber were independently dually adjudicated for appropriateness based on published criteria. The primary outcome was the correlation between the score on six questions on red blood cells (RBCs), platelets (PLTs), and plasma from the validated test and the percentage order appropriateness. Generalized linear regression was conducted to determine if factors (sex, specialty, participation in Transfusion Camp, previous transfusion education, self‐rated knowledge) were associated with appropriate orders.Results: Seventy‐four participants (45 trainees, 29 faculty; 31 females, 43 males) completed the test. Median score was 66.7% (interquartile range [IQR]: 50.0, 83.3) for six questions on RBCs, PLTs, and plasma transfusions. Of 546 transfusion orders adjudicated, appropriateness was 90.7% (95% confidence interval [CI]: 87.9%–93.0%). The correlation between prescriber test scores and order appropriateness was very weak (r = −.08). In multivariable analysis, female prescribers (p = .02) and beginner (vs. intermediate) self‐rated knowledge (p = .01) were associated with higher transfusion appropriateness.Conclusion: Transfusion knowledge test scores did not correlate with order appropriateness. Factors other than knowledge are key to understanding how to improve appropriate blood use.
- 16 September 2023
- Published by Wiley in Transfusion
- Vol. 63 (10) , 2001-2006
Canadian Blood Services traceback investigation of a suspected case of transfusion‐transmitted malaria
Background: A 4‐month‐old infant hospitalized since birth received multiple blood transfusions. In March 2022, Plasmodium falciparum was confirmed with nucleic acid testing. As the mother was assessed as unlikely to be the source of infection, the blood operator initiated a traceback investigation for a potential blood donor source. The patient had received 13 red blood cell (RBC) transfusions (aliquoted from 11 donors), 4 apheresis platelet (PLT) transfusions and 16 buffy coat pooled PLT transfusions. The blood operator medical team developed a supplementary malaria infection risk questionnaire to identify donors at highest risk of life‐time malaria infection, based on birthplace, residence, or travel in malaria‐endemic regions.Results: With 79 donors initially implicated, initial focus was on donors of RBC components. The 11 RBC donors were contacted and assessed using the supplementary questionnaire. Three donors, all of whom met current malaria‐related donor eligibility criteria, were deemed high risk of prior malaria infection. These donors consented to P. falciparum serology and nucleic acid testing (NAT). One donor who was born and had resided in an endemic West African country for 14 years, was positive for P. falciparum by serology (indirect fluorescent antibody test) and NAT‐(Ct ≥32). Lookback of this donor's transfused fresh co‐components and prior donation identified no other malaria cases.Conclusion: This was a probable transfusion‐transmitted malaria (TTM) case from an eligible donor who in retrospect was found to have unrecognized, asymptomatic, semi‐immune malaria infection, and who was potentially infectious. Blood donor lack of recall of prior malaria infection does not negate the risk of TTM from those who have lived in malaria‐endemic countries.
- 16 September 2023
- Published by Wiley in Transfusion
- Vol. 63 (10) , 2001-2006
Canadian Blood Services traceback investigation of a suspected case of transfusion‐transmitted malaria
Background: A 4‐month‐old infant hospitalized since birth received multiple blood transfusions. In March 2022, Plasmodium falciparum was confirmed with nucleic acid testing. As the mother was assessed as unlikely to be the source of infection, the blood operator initiated a traceback investigation for a potential blood donor source. The patient had received 13 red blood cell (RBC) transfusions (aliquoted from 11 donors), 4 apheresis platelet (PLT) transfusions and 16 buffy coat pooled PLT transfusions. The blood operator medical team developed a supplementary malaria infection risk questionnaire to identify donors at highest risk of life‐time malaria infection, based on birthplace, residence, or travel in malaria‐endemic regions.Results: With 79 donors initially implicated, initial focus was on donors of RBC components. The 11 RBC donors were contacted and assessed using the supplementary questionnaire. Three donors, all of whom met current malaria‐related donor eligibility criteria, were deemed high risk of prior malaria infection. These donors consented to P. falciparum serology and nucleic acid testing (NAT). One donor who was born and had resided in an endemic West African country for 14 years, was positive for P. falciparum by serology (indirect fluorescent antibody test) and NAT‐(Ct ≥32). Lookback of this donor's transfused fresh co‐components and prior donation identified no other malaria cases.Conclusion: This was a probable transfusion‐transmitted malaria (TTM) case from an eligible donor who in retrospect was found to have unrecognized, asymptomatic, semi‐immune malaria infection, and who was potentially infectious. Blood donor lack of recall of prior malaria infection does not negate the risk of TTM from those who have lived in malaria‐endemic countries.
- 9 March 2023
- Published by Wiley in Vox Sanguinis
- Vol. 118 (5) , 398-401
Use of selective phenotyping and genotyping to identify rare blood donors in Canada
Background and ObjectivesThe distribution of rare and specific red cell phenotypes varies between races and ethnicities. Therefore, the most compatible red cell units for patients with haemoglobinopathies and other rare blood requirements are most likely to be found in donors from similar genetic backgrounds. Our blood service introduced a voluntary question asking donors to provide their racial background/ethnicity. Results triggered additional phenotyping and/or genotyping. Materials and MethodsWe analysed the results of additional testing performed between January 2021 and June 2022, and rare donors were added to the Rare Blood Donor database. We determined the incidence of various rare phenotypes and blood group alleles based on donor race/ethnicity. ResultsOver 95% of donors answered the voluntary question; 715 samples were tested, and 25 donors were added to the Rare Blood Donor database, including five k-, four U-, two Jk(a-b-) and two D- - phenotypes. ConclusionAsking donors about their race/ethnicity was well received by donors, and the resulting selective testing enabled us to identify individuals with a higher likelihood of being rare blood donors, support patients with rare blood requirements and better understand the incidence of common and rare alleles and red blood cell phenotypes in the Canadian donor population.
- 9 March 2023
- Published by Wiley in Vox Sanguinis
- Vol. 118 (5) , 398-401
Use of selective phenotyping and genotyping to identify rare blood donors in Canada
Background and ObjectivesThe distribution of rare and specific red cell phenotypes varies between races and ethnicities. Therefore, the most compatible red cell units for patients with haemoglobinopathies and other rare blood requirements are most likely to be found in donors from similar genetic backgrounds. Our blood service introduced a voluntary question asking donors to provide their racial background/ethnicity. Results triggered additional phenotyping and/or genotyping. Materials and MethodsWe analysed the results of additional testing performed between January 2021 and June 2022, and rare donors were added to the Rare Blood Donor database. We determined the incidence of various rare phenotypes and blood group alleles based on donor race/ethnicity. ResultsOver 95% of donors answered the voluntary question; 715 samples were tested, and 25 donors were added to the Rare Blood Donor database, including five k-, four U-, two Jk(a-b-) and two D- - phenotypes. ConclusionAsking donors about their race/ethnicity was well received by donors, and the resulting selective testing enabled us to identify individuals with a higher likelihood of being rare blood donors, support patients with rare blood requirements and better understand the incidence of common and rare alleles and red blood cell phenotypes in the Canadian donor population.